
Abstract Background Prostate-specific antigen (PSA) is widely used for screening and diagnosis of prostate cancer. Variation in PSA levels is influenced by age, genetics, and other factors, yet this variation has not been well characterized in African men. Methods We used data on serum PSA extracted from medical records from prostate cancer cases and controls collected as part of the Men of African Descent and Carcinoma of the Prostate (MADCaP) network. We evaluate the association of PSA levels with country of origin, age, body mass index (BMI), and polygenic risk score. Results The median PSA levels were 41.8 (0.2-9696) ng/mL in 1907 prostate cancer cases and 1.235 (0.01-9.72) ng/mL in 902 controls. Higher PSA levels were associated with increasing age, lower BMI, higher Gleason score, and more advanced tumor stage in cases, explaining approximately 35% of variation in log-transformed PSA levels. In controls, 4.8% of PSA variation was explained by age. Conclusion Our data in African men are consistent with non-African studies that report PSA levels increase with age, inversely with BMI (suggesting a PSA dilution effect or reverse causation), and with more aggressive disease in cases. These data may be used to help understand PSA distributions and in the future may guide screening practices in African men.
Abstract Early and continuous antiretroviral therapy (ART) reduces cancer risk in people with HIV (PWH), yet residual risk potentially driven by persistent B-cell activation remains. We used observational and genetic triangulation to evaluate whether baseline B-cell biomarkers are associated with subsequent cancer risk. We conducted: (i) a nested case-control study within the INSIGHT trials (158 cases and 313 matched controls) assessing B-cell biomarkers (sCD23, sCD27, sCD30, CXCL13) in PWH; and (ii) two-sample Mendelian randomization (MR) to evaluate likely causal relationships between these proteins and 23 cancer types using general-population genome-wide association studies. Median time from study entry to cancer diagnosis was 2.9 years. In PWH, CXCL13 was associated with overall cancer risk (highest tertile vs. lowest tertile OR 2.36, 95% CI 1.24–4.5), driven by infection-related cancers (N = 82; OR 4.81, 1.76–13.1) and lymphoma (N = 36; OR 9.92, 1.58–62.2). The CXCL13 association remained robust among virally suppressed participants (P = 0.018). sCD30 was also associated with infection-related cancers (OR 2.77, 1.09–7.03). sCD23 showed a linear association with infection-related cancer (OR per SD 1.42, 1.01-2.00), though tertile-based analyses were non-significant. In the general population, MR meta-analyses showed null associations for these biomarkers across 23 cancer types (P > 0.05). Our study links B-cell markers with cancer risk in PWH, identifying CXCL13 as a marker of infection-related cancer risk despite effective ART, highlighting a "residual inflammatory gap" for modern risk stratification. The lack of causal MR signals suggests these proteins are markers of HIV-associated immune activation rather than universal etiological factors for cancer.
Abstract Background Survivors of childhood cancer (CCS) have higher risk of developing ischaemic heart disease (IHD), however, data on coronary anatomy, revascularisations, and prognosis remain limited. The objective was to investigate angiographic findings, invasive treatment patterns and mortality in CCS with IHD compared with controls without a history of childhood cancer. Methods This was a nationwide retrospective cohort-study of all 5-year survivors of leukaemia, lymphoma, or central nervous system cancer who subsequently developed IHD, with index cancer between 1958-2021. CCS were compared with population-based controls with IHD matched on cancer date by age, sex and residence. Results 136 CCS and 667 controls with IHD were included. CCS were a median of 5.2 years younger than controls at diagnosis of IHD. CCS had a higher prevalence of left main coronary artery (LMCA) stenosis (25.0% vs. 6.5%; p < 0.001) and multivessel disease (51.2% vs. 39.4%; p = 0.043). Coronary artery bypass grafting (CABG) was more frequently performed in CCS (22.8% vs. 11.4%; p < 0.001), although after adjusting for relevant covariates the difference was attenuated. After a median follow-up of 5.4 years following IHD diagnosis, CCS had higher hazard of all-cause mortality (HR 1.83, 95% CI 1.31-2.54; p < 0.001) and cardiovascular mortality (HR 2.04; 95% CI 1.42-2.95; p < 0.001). Conclusions CCS who developed IHD demonstrate a higher burden of extensive coronary artery disease, characterized by increased prevalence of LMCA stenosis and multivessel disease. Although overall revascularisation rates were similar, CCS experienced significantly higher all-cause and cardiovascular mortality following IHD-diagnosis compared with controls.
Abstract Background U.S. Preventive Services Task Force (USPSTF) lung cancer screening (LCS) eligibility relies on smoking history data that are often incomplete or inaccurate in Electronic Health Records (EHRs). Inaccurate data combined with clinicians’ unfamiliarity with LCS recommendations may lead to guideline-discordant screening, potentially reducing the benefit-risk ratio and misallocating resources. Limited data exist that describe USPSTF-ineligible patients who receive and complete LCS orders. Methods We conducted a retrospective cohort study of adults receiving an LCS order at Kaiser Permanente Colorado (5/1/2014-12/31/2023). Using structured EHR data to determine eligibility, we assessed USPSTF-ineligible LCS orders, screening completion rates, and lung cancer yield. Results Of 15,624 patients receiving LCS orders, 2,048 (13%) were classified as USPSTF-ineligible. Most ineligibility resulted from incomplete (28%) or out-of-range smoking history data (54%). USPSTF-ineligible patients were more likely to be female and affluent and less likely to be White, aged 55-80, or currently smoke. Orders were more common during program rollout and the COVID-19 pandemic. Among ineligible patients, 47% completed screening; 3% were diagnosed with lung cancer, 67% at an early stage. Lung cancer detection was 8% among Positive screens (Lung-RADS 3-4) and 1% among Negative screens (Lung-RADS 1-2). Conclusions A substantial proportion of patients receiving lung cancer screening orders were classified as USPSTF-ineligible using structured EHR data, primarily because of incomplete or out-of-range smoking histories. The unexpectedly high lung cancer detection rate suggests that many may have been misclassified rather than truly ineligible. These findings highlight the challenges of utilizing EHR data to identify guideline-discordant screening rates.